GlassScriptPhysician profile
Samarea Denise Webb
NPI 1396258422
$5,053.96
in general payments reported to CMS, 2019-2025
27 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.21 · 2022: $449 · 2023: $1,237 · 2024: $1,466 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,500 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,500.40 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,057.07 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $773.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $628.45 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $508.56 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $423.28 | 2023-2025 | |
| Pfizer INC. | $229.92 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.43 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $213.27 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.56 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $170.42 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $101.85 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $94.75 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $70.68 | 2023-2024 | Yupelri |
| Dexcom, INC. | $51.97 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $48.02 | 2023-2024 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.54 | 2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $35.28 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $33.88 | 2022 | |
| Viatris Specialty LLC | $29.91 | 2025 | Yupelri |
| Abbott Laboratories | $19.22 | 2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $18.92 | 2023 | Evkeeza |
| Inspire Medical Systems, INC. | $16.19 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $15.28 | 2025 | Symbravo |
| Ultragenyx Pharmaceutical INC. | $15.16 | 2022 | |
| Amgen INC. | $14.11 | 2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $13.73 | 2022 | |
| Sanofi Pasteur INC. | $13.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samarea Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.